Clinical Trial Update: TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer [Phase 3]

View source ↗

Summary

Amgen's TRINOVA-3 Phase 3 trial evaluating AMG 386 with paclitaxel and carboplatin for ovarian, fallopian tube, and peritoneal cancers has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• AMG-386 (trebananib)
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Amgen | Conditions: Fallopian Tube Cancer, Ovarian Cancer | Phase 3 | Status: TERMINATED